Lin Shao-Lee

Chief Executive Officer at CUE; Chief Executive Officer at SLRN

Sold, on record
$1.9M
Dollars the filings state
Form 4 sales
4
Latest Aug 13, 2026
Form 144 notices
0
Proposed sales
Companies
2
Filed as an executive or holder

Companies

  • CUECue Biopharma, Inc.Chief Executive Officer
  • SLRNACELYRIN, Inc.Chief Executive Officer

Sales by reason

0
Routine
0
Plan not stated
1
No plan
0
Unusual
Stacked: routine sales under a plan, sales whose filing does not state a plan, sales with no plan, and unusual sales.

Form 4 sales per month, last 12 months.

Sales chart range

Sales by company

Shares sold, every Form 4 sale on record.

Timeline

  1. 1 Form 4 sale SLRNNo plan
    Jan 2, 2024 2024

    Sold 10,691 shares at $7.41 ($79k)

    Lin Shao-Lee, Chief Executive Officer

    No 10b5-1 planSold 0.7% of holdings ($12M position)1.6M shares leftFirst sale on recordFiling

  2. 2 Form 4 sale SLRNNo plan
    Feb 20, 2024 +49 days

    Sold 15,701 shares at $7.60 ($119k)

    Lin Shao-Lee, Chief Executive Officer

    No 10b5-1 planSold 1% of holdings ($12.2M position)1.6M shares leftFiling

  3. 3 Form 4 sale SLRNNo plan
    Apr 1, 2024 +41 days

    Sold 9,961 shares at $6.63 ($66k)

    Lin Shao-Lee, Chief Executive Officer

    No 10b5-1 planSold 0.6% of holdings ($10.5M position)1.6M shares leftFiling

  4. 4 Form 4 sale CUENo plan
    Aug 13, 2026 +864 days

    Sold 58,258 shares at $27.58 ($1.6M)

    Lin Shao-Lee, Chief Executive Officer

    No 10b5-1 planSold 7.6% of holdings ($21.1M position)705,995 shares leftFirst sale on recordFiling

Every transaction

Loading transactions…

Sales and notices (4)

Form 144 notices and Form 4 sales by Lin Shao-Lee
Source
Aug 13, 2026Aug 14, 2026CUEChief Executive OfficerForm 4 sale58,258$1.6M7.6%No planSEC
Apr 1, 2024Apr 3, 2024SLRNChief Executive OfficerForm 4 sale9,961$66k0.6%No planSEC
Feb 20, 2024Feb 22, 2024SLRNChief Executive OfficerForm 4 sale15,701$119k1.0%No planSEC
Jan 2, 2024Jan 4, 2024SLRNChief Executive OfficerForm 4 sale10,691$79k0.7%No planSEC